Cansino Cost Of Revenue from 2010 to 2024

688185 Stock   61.23  0.13  0.21%   
Cansino Biologics' Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Cost Of Revenue is expected to dwindle to about 617.7 M. From 2010 to 2024 Cansino Biologics Cost Of Revenue quarterly data regression line had arithmetic mean of  335,031,076 and r-squared of  0.47. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
1.2 B
Current Value
617.7 M
Quarterly Volatility
493 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cansino Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cansino Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 27.1 M, Interest Income of 105.1 M or Interest Expense of 67.4 M, as well as many indicators such as . Cansino financial statements analysis is a perfect complement when working with Cansino Biologics Valuation or Volatility modules.
  
This module can also supplement various Cansino Biologics Technical models . Check out the analysis of Cansino Biologics Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Cansino Stock

Cansino Biologics financial ratios help investors to determine whether Cansino Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cansino with respect to the benefits of owning Cansino Biologics security.